Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis

Sponsor
Jochen Schmitt.
Study ID
NCT01812954
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
16 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Methotrexate — DRUG
  • Cyclosporins — DRUG
  • fumaric acid — DRUG
  • Acitretin — DRUG
  • Infliximab — DRUG
  • etanercept — DRUG
  • Adalimumab — DRUG
  • Ustekinumab — DRUG

Study Details

This study is health economic analysis of medicinal treatment options for moderate-to-severe psoriasis vulgaris from the societal perspective. Efficacy data and other clinical outcomes will be derived from an up-to-date meta-analysis of randomized clinical trials (RCTs) for moderate-to-severe psoriasis. Direct and indirect costs will be extracted from various different sources, including summary of product characteristics (SPCs) and the German S3 guideline on psoriasis care, health care utilization data and official statistics. The study aims to investigate the comparative cost-effectiveness of biologic and conventional systemic treatments currently (as of June 1st, 2012) approved for moderate-to-severe plaque-type psoriasis in Germany. Effectiveness will be measured by means of the pooled (Psoriasis Area and Severity Index) PASI-75 response rates as reported in RCTs Direct cost as well as indirect cost will be considered.

Key Dates

Start date
Mar 31, 2013
Status verified
Aug 2017
Primary completion
Jun 30, 2014
Completion
Jun 30, 2014

Study Design

Enrollment
1 participants (actual)

Primary Outcome Measure

Cost per quality-adjusted life year (QALY) gained through treatment with each individual agent compared to supportive care as well as compared to placebo [ Time Frame: 1 year ]

Related Studies